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NEWS AND PERSPECTIVES
Dengue Disease
Dengue fever (DF) is an acute infectious disease
that is caused by four serotypes of dengue virus.
It is characterized by biphasic fever, myalgia,
headache, pain in various parts of the body, rash,
lymphadenopathy, and leukopenia.1,2 DF is self-
limited, but it does progress to dengue hemor-
rhagic fever (DHF) or dengue shock syndrome
(DSS) under certain conditions. DHF is a severe
febrile disease characterized by abnormalities of
hemostasis and increased vascular permeability,
and in more severe cases, it may progress to DSS.
DSS is a form of hypovolemic shock that is as-
sociated clinically with hemoconcentration and
hemorrhage; it can be fatal if suitable fluid sup-
plementation is not given.
Dengue disease is the most important arbovi-
ral disease in humans, and occurs in tropical coun-
tries where over 2.5 billion people are at risk of
infection. The WHO has estimated that 50–100
million cases of DF and several hundred thousand
cases of DHF occur each year, depending on the
epidemic activity. DHF is the leading cause of hos-
pitalization for children in Southeast Asia. Den-
gue virus can be transmitted to infants, children,
and adults by the vectors Aedes aegypti and Aedes
albopictus. The epidemiology in different areas is
distinct. In endemic areas such as Southeast Asia or
Latin America, dengue infection occurs through-
out the year, and peaks during the rainy season.
On the other hand, in Taiwan, a non-endemic
area, dengue cases can be classified into indige-
nous or imported cases.3,4 Most indigenous den-
gue cases can be traced back to imported cases
that precede local transmission. If the index case
patient who carries the imported dengue virus 
is not identified early, thereby breaking the virus
transmission chain as quickly as possible, then
dengue virus will spread through the mosquito
population to infect other individuals, and cause
a local dengue outbreak. The outbreaks usually
peak around September to December. After an
outbreak, local environmental protection bureaus
make substantial efforts to reduce the vector
source, with the outbreaks being finally brought
under control with the help of the cold weather
that arrives in late December or early January in
the following year. This unique pattern of den-
gue transmission in Taiwan repeats every year:
beginning by importation from Southeast Asia in
the early summer, spreading out through Southern
Taiwan in the fall, and ending because of cold
weather in the winter. Although all four serotypes
of dengue virus are imported and have been iso-
lated from various regions of Taiwan, one serotype
usually dominates in each particular year.
Other demographic differences between den-
gue in Southeast Asia and Taiwan are patient age
and the status of dengue infection.5,6 In Southeast
Asia, most of the DHF/DSS patients are children,
while some are infants. Childhood DHF is caused
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by secondary infection, whereas infant DHF re-
sults from primary infection. The antibody-
dependent enhancement (ADE) hypothesis was
formulated to explain this epidemiologic obser-
vation.7 Severe DHF/DSS cases occur in children
who experience a second dengue virus infection
that has a different serotype from the previous
one. Newborn babies aged < 1 year who acquire
maternal anti-dengue IgG antibody are also more
susceptible to developing DHF/DSS after primary
infection.8 When anti-dengue antibodies decay to
the limit of neutralization, they enhance rather
than combat the virus infection, and thus facili-
tate the development of DHF. However, in Taiwan
the scenario is different. A. aegypti displays day-
biting behavior that prefers to feed on working
adults. Most people are naïve to dengue virus
and have no prior anti-dengue antibodies—this
enhances the development of dengue disease.
Adults have a strong immune response, and the
majority of symptomatic dengue cases are in
adults, with a peak at the 45–55 year age range, in
contrast to secondary-infection-associated DHF
in children. Elderly patients with dengue infec-
tion have more severe DHF, which is sometimes
fatal. Although secondary infection with sero-
type 2 virus increases the risk of DHF, primary in-
fection with serotype 1 or 3 can still lead to
development of DHF/DSS. Other underlying dis-
eases such as chronic renal insufficiency, hypo-
tension, or diabetes can increase the risk of fatal
DHF/DSS.9
Dengue-virus-induced disease has its own
unique features. DHF is an acute vascular per-
meability syndrome that is accompanied by ab-
normalities in hemostasis. The clinical features
include plasma leakage, a tendency to bleed, and
liver involvement. Capillary leakage develops rap-
idly over a period of hours, near or at the end of
the febrile period when the symptoms of classic
DF resolve. Pleural effusion, ascites, and hemo-
concentration are indicative of intravascular vol-
ume loss. This can progress quickly to shock if
patients do not receive intravascular fluid resus-
citation. The hemorrhagic manifestations range
from a positive tourniquet test to spontaneous
bleeding from the nose or the gastrointestinal
tract. Hemoconcentration and marked thrombo-
cytopenia are two major characteristic features of
DHF/DSS. How the endothelial cells and plate-
lets are specifically damaged in the progressive
development of DHF/DSS, directly or indirectly,
needs to be addressed.
Hypotheses on the Pathogenesis 
of DHF
Several hypotheses for the pathogenesis of 
DHF have been proposed. Among these, ADE is
thought to play the central role.7 The ADE hy-
pothesis was formulated to explain the epidemi-
ological observation of secondary infection in
childhood DHF and primary infection in infant
DHF. However, the association of DHF/DSS with
prior immunity to other dengue serotypes by it-
self explains neither the pathogenetic basis of the
association nor the molecular basis of the clini-
cal manifestations of DHF/DSS. It is not clear
how augmentation of dengue virus infection by
enhancing antibodies leads to DHF/DSS.
Virus virulence is the capacity of a virus to
produce disease in a host, and is an alternative
hypothesis for the pathogenesis of DHF/DSS.
Viral load is a contributing factor in the develop-
ment of DHF/DSS. The different manifestations
of DF, DHF, and DSS may be caused by variants
of dengue virus with different degrees of viru-
lence. The risk of DHF/DSS is higher in second-
ary infections with dengue virus of serotype 2
than other serotypes.10 Although structural differ-
ences have been found also among various iso-
lates of DF and DHF patients,11 Asian genotype
dengue-2 is more virulent than the American
genotype dengue-2.12 However, persons infected
with the same dengue virus have different clini-
cal manifestations, which suggests that host fac-
tors play important roles in the development of
dengue disease.
The typical virus load undergoes dynamic
changes, varies between individuals, and some-
times varies from day-to-day post-infection. It
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eventually declines quickly on the day that fever
subsides. This reflects the virulence, the high
growth rate in vivo, and the consequences of the
host immune response. Immunopathogenesis is
thought to be the major factor in the development
of DHF/DSS.13 The theory of cross-reactive T cells
expanding during secondary infection—with cy-
tokine storms of interferon (IFN)-γ, interleukin-2
and tumor necrosis factor-α, and complement 
to induce plasma leakage of endothelial cells—
is deficient, because it does not explain cases of
infant DHF with primary infection. Not all DHF/
DSS cases are secondary infections. Furthermore,
DHF develops rapidly, usually over a period of
hours, and resolves within 1–2 days in patients
who receive appropriate fluid resuscitation. No
discernible sequelae are usually found. This sce-
nario is not reconciled easily with the known 
tissue-destructive effects of inflammatory cyto-
kines. Therefore, any theory that explains the
pathogenesis or immunopathogenesis of DHF/
DSS in infants, children and the elderly must ac-
count for the unique clinical, pathological, and
epidemiological features of dengue virus disease.
Hemophagocytosis in Dengue Disease
Dengue virus infection causes intense immune
activation. Aberrant immune responses such as
cytokine overproduction and generation of au-
toantibodies that act against platelets and en-
dothelial cells occur after dengue virus infection.
Molecular mimicry between platelets or endo-
thelial cells and NS1 or prM of dengue virus may
explain the cross-reactive properties of anti-NS1
or anti-prM antibodies to host cells, and the attack
of platelets and endothelial cells during disease
development.14 Dengue virus can cause severe
hemophagocytic syndrome.15–17 Serum ferritin is
a macrophage activation marker in vivo, and is
highly elevated in dengue patients. Monocytes or
macrophages are activated by IFN-γ or dengue
virus infection. The activated macrophages then
phagocytose autoantibody-coated platelets and
endothelial cells and thus contribute to the 
destruction of these targeted cells. Anti-dengue 
antibodies become pathogenic and may enhance
dengue disease severity. The anti-NS1 and anti-prM
cross-reactive antibody action against platelets
and endothelial cells explains the target specificity
and unique features of thrombocytopenia and
plasma leakage observed during the development
of DHF/DSS. The timing of macrophage activa-
tion by IFN-γ is critical and explains the transient
event of DHF during defervescence. Adults have 
a stronger immune response to dengue virus
than children and are more likely to be sympto-
matic. Since elderly patients have inflammation-
associated underlying diseases, such as chronic
renal insufficiency or diabetes, autoimmunity
and activated macrophages sustain the inflam-
matory response and cause a high fatality rate for
DHF in the elderly.
Unresolved Issues in Dengue Disease
Dengue disease has several distinct features among
virus-induced diseases. Secondary dengue virus
infection develops into more severe DHF/DSS
than primary infection does, especially when the
second infection is caused by serotypes different
from the previous ones. This is an exception to
the normal rule of immune responses protecting
against subsequent infection—instead, previous
immunity enhances the disease process. DHF/
DSS is a systemic disease with unique clinical
manifestations of thrombocytopenia and plasma
leakage, which are distinct from those of other
viral diseases. Furthermore, dengue virus infection
can cause autoimmunity, which plays a patho-
genic role in the disease process. The self-tolerance
is presumably broken by molecular mimicry be-
tween dengue virus and autoantigens. Several 
issues remain to be addressed in future research,
including: the identity of authentic dengue virus
receptors;18 the mechanism by which antibodies
enhance virus replication; how autoimmunity is
induced after dengue virus infection; and how
enhancing antibodies participate in dengue 
immunopathogenesis.
Hemophagocytosis in dengue immunopathogenesis
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Impact of Autoantibody-associated
Transient Hemophagocytosis in Dengue
Vaccination or Therapy
Autoantibody-associated macrophage activation
participates in many viral diseases,19 and since it
has been identified as the key factor for progres-
sion of DHF/DSS after dengue virus infection,15
several current hypotheses need to be reexamined.
The safety of live attenuated dengue vaccine cur-
rently under development20 has become a crucial
issue. The induction of autoimmunity after at-
tenuated dengue virus immunization will be of
great concern in the future. Will a more severe
disease be induced by subsequent dengue virus
infection in vaccinated persons because of the es-
tablished memory of the autoimmunity? Can a
dengue vaccine be developed that only generates
neutralizing activity, without enhancing or patho-
genic autoantibody activity? Furthermore, while
the current therapy of fluid resuscitation for
childhood DHF is acceptable, this is not the case
in old age. Therefore, we need an early biomarker
for the prediction of DHF progression, and to in-
vestigate more appropriate interventions to treat
DHF in elderly patients.
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